Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million...
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million...
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Thursday after market hours. Here’s what to look for. Corcept m...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF (NYSEARCA: XBI) and the Nasdaq Biotechnology Index (NASDAQ: IBB) struggled to find their footing in late March 2026, dropping
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500 and Nasdaq Composite indices tumbled over 1.5% due to lingering inflation concerns and a surprise hawkish pivot
Shareholders of Corcept would probably like to forget the past six months even happened. The stock dropped 56.3% and now trades at $36.31. This was partly dr...
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the company’s market capitalization, was triggered by a "perfect storm" of positive regulatory developments and breakthrough clinical
March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of Lifyorli™ (relacorilant) for platinum-resistant ovarian cancer (PROC). This approval, coming four months ahead of its scheduled PDUFA date, marks Corcept's transition from a niche endocrinology player into [...]
Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...
